These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21035622)

  • 1. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?
    Cummings J
    Biol Psychiatry; 2010 Nov; 68(10):876-8. PubMed ID: 21035622
    [No Abstract]   [Full Text] [Related]  

  • 2. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
    Schor NF
    Ann Neurol; 2011 Feb; 69(2):237-9. PubMed ID: 21387368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.
    Imbimbo BP; Peretto I
    Curr Opin Investig Drugs; 2009 Jul; 10(7):721-30. PubMed ID: 19579178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
    Doody RS; Raman R; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; He F; Sun X; Thomas RG; Aisen PS; ; Siemers E; Sethuraman G; Mohs R;
    N Engl J Med; 2013 Jul; 369(4):341-50. PubMed ID: 23883379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecule of the month. Semagacestat.
    Drug News Perspect; 2008 Sep; 21(7):390. PubMed ID: 19259551
    [No Abstract]   [Full Text] [Related]  

  • 6. [Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
    Trechot P; Schmutz JL
    Ann Dermatol Venereol; 2013 Oct; 140(10):669-70. PubMed ID: 24090904
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.
    Carlson C; Estergard W; Oh J; Suhy J; Jack CR; Siemers E; Barakos J
    Alzheimers Dement; 2011 Jul; 7(4):396-401. PubMed ID: 21784350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons from a failed γ-secretase Alzheimer trial.
    De Strooper B
    Cell; 2014 Nov; 159(4):721-6. PubMed ID: 25417150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).
    Hopkins CR
    ACS Chem Neurosci; 2010 Aug; 1(8):533-4. PubMed ID: 22778845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond.
    De Strooper B; Chávez Gutiérrez L
    Annu Rev Pharmacol Toxicol; 2015; 55():419-37. PubMed ID: 25292430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.
    Rosenberg PB; Lanctôt KL; Herrmann N; Mintzer JE; Porsteinsson AP; Sun X; Raman R
    J Alzheimers Dis; 2016 Aug; 54(1):373-81. PubMed ID: 27567808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues.
    Samson K
    Ann Neurol; 2010 Oct; 68(4):A9-A12. PubMed ID: 20976761
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.
    Henley DB; May PC; Dean RA; Siemers ER
    Expert Opin Pharmacother; 2009 Jul; 10(10):1657-64. PubMed ID: 19527190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor.
    Hsu CK; Hsu CC; Lee JY; Kuo YM; Pai MC
    J Am Acad Dermatol; 2013 Feb; 68(2):e46-8. PubMed ID: 23317986
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings.
    Henley DB; Sundell KL; Sethuraman G; Dowsett SA; May PC
    Curr Med Res Opin; 2014 Oct; 30(10):2021-32. PubMed ID: 24983746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semagacestat for treatment of Alzheimer's disease.
    Doody RS; Aisen PS; Iwatsubo T
    N Engl J Med; 2013 Oct; 369(17):1661. PubMed ID: 24152267
    [No Abstract]   [Full Text] [Related]  

  • 17. Semagacestat for treatment of Alzheimer's disease.
    Gupta VB; Gupta VK; Martins R
    N Engl J Med; 2013 Oct; 369(17):1660-1. PubMed ID: 24152268
    [No Abstract]   [Full Text] [Related]  

  • 18. Semagacestat for treatment of Alzheimer's disease.
    Pomara N
    N Engl J Med; 2013 Oct; 369(17):1661. PubMed ID: 24152269
    [No Abstract]   [Full Text] [Related]  

  • 19. Alzheimer's failure raises questions about disease-modifying strategies.
    Extance A
    Nat Rev Drug Discov; 2010 Oct; 9(10):749-51. PubMed ID: 20885394
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
    Siemers ER; Quinn JF; Kaye J; Farlow MR; Porsteinsson A; Tariot P; Zoulnouni P; Galvin JE; Holtzman DM; Knopman DS; Satterwhite J; Gonzales C; Dean RA; May PC
    Neurology; 2006 Feb; 66(4):602-4. PubMed ID: 16505324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.